Author

Sayda M. Elbashir

Moderna Therapeutics (United States)ORCID 0000-0001-6250-9679Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Assay:metagenomics· 1

Frequent Co-Authors

Darin K. EdwardsiD· 3 shared Amy Gorrie· 2 shared Andrea Carfı́iD· 2 shared Arshan NasiriD· 2 shared Daniela Montes Berrueta· 2 shared Diana Wing LeeiD· 2 shared Hardik JaniiD· 2 shared Kath Hardcastle· 2 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Darin K. EdwardsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 16, 2025

mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses

Arshan Nasir, Diana Wing Lee, Ziqiu Wang…·Alec W. Freyn

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

1 citation

mouseexperimental assay

𝕏 PostBluesky

ImmunologyVaccinePeer-reviewedMar 7, 2025

mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice

Diana Wing Lee, Arshan Nasir, Sayda M. Elbashir…·Yadunanda Budigi

This study evaluates JN.1 and KP.2 mRNA vaccines in mice, showing they elicit strong neutralizing antibodies against JN.1 subvariants and cross-neutralize KP.3, LA.2, and XEC.

16 citationstop 1%

mouseexperimental assay

𝕏 PostBluesky

MicrobiologyJournal of VirologyPeer-reviewedAug 28, 2024

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain

Baoling Ying, Chieh-Yu Liang, Pritesh Desai…·Michael Diamond

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

8 citations

mouseproteomics

𝕏 PostBluesky